Tracks biomarkers in people with leukemia or follicular lymphoma
Observes blood and marrow samples from people with leukemia or follicular lymphoma.
Plain-language title generated from the registry record
Registry title: A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
Key facts
- Where
- Bethesda, Charlotte, Cincinnati, Columbus, Fargo, Iowa City, Maumee, Reno, Rochester, Sioux Falls, St Louis, and York, United StatesSee the 13 sites
Where in United States
- The Center for Cancer and Blood DisordersBethesda, United StatesTaking people
- Novant Health Weisiger Cancer InstituteCharlotte, United StatesTaking people
- University of CincinnatiCincinnati, United StatesTaking people
- OhioHealth Research InstituteColumbus, United StatesTaking people
- Sanford FargoFargo, United StatesTaking people
- University of Iowa Hospital and ClinicsIowa City, United StatesTaking people
- Taylor Cancer Research CenterMaumee, United StatesTaking people
- Cancer Care Specialists of RenoReno, United StatesTaking people
- University of RochesterRochester, United StatesTaking people
- Avera Cancer InstitueSioux Falls, United StatesTaking people
- Sanford Sioux FallsSioux Falls, United StatesTaking people
- Washington University in St. LouisSt Louis, United StatesTaking people
- Cancer Care Associates of YorkYork, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tempus AI
- Trial code
- NCT07154823
- Record updated
- 9 October 2026
- Original description
The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood draws and the acquisition of leftover tissue and/or bone marrow aspirates during their routine therapy and disease monitoring. The primary goal is to understand the association between biomarkers and real-world clinical outcomes in these patient populations.Read full original descriptionShow less
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood draws and the acquisition of leftover tissue and/or bone marrow aspirates during their routine therapy and disease monitoring. The primary goal is to understand the association between biomarkers and real-world clinical outcomes in these patient populations.
All Cohorts Inclusion Criteria:; Willing and able to participate in the research and provide biospecimens; Willing and able to provide informed consent; Cohort 001 Inclusion:; Have documented diagnosis of AML according to the World Health Organization (WHO) classification; Secondary AML is allowed; Cohort 002 Inclusion:; Histologically confirmed diagnosis of Follicular Lymphoma (Subgroups A-D); Submission of baseline sample representative of current disease per laboratory manual (Subgroups A-D); 002A (Newly Diagnosed Active Observation): On active observation for 6 more or less, or intended for active observation; 002B (Newly Diagnosed, High Risk): Intended for first line treatment; 002B (Newly Diagnosed, High Risk): Meets the criteria for high risk by any of the following: Follicular Lymphoma Inernational Prognostic Index (FLIPI) High Risk, Groupe d'Etude des Lymphomes Follicularies (GELF) High Tumor Burden, Lactate Dehydrogenase (LDH) above the upper limit of normal (ULN); 002C (Relapsed / Refractory High Risk POD24 FL): Documented progression of disease within 24 months (POD24) of first line follicular lymphoma treatment, prior to second line treatment; 002D (Transformed FL): Pathologically confirmed transformation; All Cohorts Exclusion Criteria:; Not willing or able to adhere with the study procedures; Cohort 001:; Have received any prior therapy intended for standard of care (SoC) treatment of AML; Cohort 002:; 002A: Received prior treatment for follicular lymphoma; 002A: Diagnosed with High Risk follicular lymphoma by any of the following definitions: FLIPI High Risk, GELF High Tumor Burden, LDH above ULN; 002A: Resected patients with NED; 002B: Intended for active observation; 002B: Received prior treatment for follicular lymphoma.